NYSEAMERICAN : IGC
IGC Pharma, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 0.185 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 19.13M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 19.13M |
| Enterprise Value | 18.14M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 103.38M |
| Shares Outstanding | 103.38M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 13.22% |
| Owned by Institutions (%) | 22.10% |
| Float | 89.72M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 17.29 |
| Forward PS | 19.96 |
| PB Ratio | 2.10 |
| P/TBV Ratio | 5.95 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 16.40 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.32 |
| Quick Ratio | 0.79 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -83.34% |
| Return on Assets (ROA) | -50.31% |
| Return on Invested Capital (ROIC) | -63.56% |
| Return on Capital Employed (ROCE) | -98.37% |
| Weighted Average Cost of Capital (WACC) | 6.83% |
| Revenue Per Employee | $15,800 |
| Profits Per Employee | -$92,086 |
| Employee Count | 70 |
| Asset Turnover | 0.11 |
| Inventory Turnover | 0.55 |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.48 |
| 52-Week Price Change | -54.23% |
| 50-Day Moving Average | 0.27 |
| 200-Day Moving Average | 0.28 |
| Relative Strength Index (RSI) | 18.74 |
| Average Volume (20 Days) | 611,047 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 635,640 |
| Short Previous Month | 1.07M |
| Short % of Shares Out | 0.61% |
| Short % of Float | 0.71% |
| Short Ratio (days to cover) | 0.94 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 1.11M |
| Gross Profit | 511,000 |
| Operating Income | -8.10M |
| Pretax Income | -6.45M |
| Net Income | -6.45M |
| EBITDA | -7.52M |
| EBIT | -8.10M |
| Loss Per Share | -$0.08 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 1.13M |
| Total Debt | 146,000 |
| Net Cash | 984,000 |
| Net Cash Per Share | $0.01 |
| Equity (Book Value) | 8.09M |
| Book Value Per Share | 0.09 |
| Working Capital | 490,000 |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -5.54M |
| Capital Expenditures | -82,000 |
| Depreciation & Amortization | 571,000 |
| Net Borrowing | -3,000 |
| Free Cash Flow | -5.63M |
| FCF Per Share | -$0.05 |
Margins
| Measure | Value |
|---|
| Gross Margin | 46.20% |
| Operating Margin | -731.92% |
| Pretax Margin | -582.82% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -19.49% |
| Shareholder Yield | -19.49% |
| Earnings Yield | -42.14% |
| FCF Yield | -29.42% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Apr 19, 2013 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -10.12 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |